(Reuters) -Novocure ( NVCR ) said on Wednesday that its cancer therapy met the main goal of a late-stage trial testing it as a treatment for a type of lung cancer.
The therapy along with supportive care slowed the spreading of cancer to the brain to 21.9 months compared to 11.3 months for supportive care alone.
Novocure ( NVCR ) said it plans to submit the data to regulatory authorities.